$1.17 Billion is the total value of Logos Global Management LP's 59 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 48.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NKTX | Sell | NKARTA INC | $103,406,000 | +68.0% | 1,682,178 | -17.8% | 8.86% | +12.6% |
| TGTX | Sell | TG THERAPEUTICS INC | $44,217,000 | -5.6% | 850,000 | -51.4% | 3.79% | -36.7% |
| ATHA | Sell | ATHIRA PHARMA INC | $32,465,000 | +72.3% | 947,873 | -7.1% | 2.78% | +15.4% |
| KROS | Sell | KEROS THERAPEUTICS INC | $31,743,000 | -48.6% | 450,000 | -71.9% | 2.72% | -65.5% |
| RPTX | Sell | REPARE THERAPEUTICS INC | $23,217,000 | -22.8% | 676,894 | -30.7% | 1.99% | -48.3% |
| BTAI | Sell | BIOXCEL THERAPEUTICS INC | $19,866,000 | -16.7% | 430,000 | -21.8% | 1.70% | -44.2% |
| RNA | Sell | AVIDITY BIOSCIENCES INC | $17,136,000 | -15.6% | 671,454 | -6.9% | 1.47% | -43.5% |
| CMPS | Sell | COMPASS PATHWAYS PLCsponsored ads | $14,292,000 | -18.1% | 300,000 | -40.0% | 1.22% | -45.1% |
| CALT | Sell | CALLIDITAS THERAPEUTICS ABsponsered ads | $10,086,000 | -23.6% | 300,000 | -45.5% | 0.86% | -48.8% |
| NRIX | Sell | NURIX THERAPEUTICS INC | $7,572,000 | -21.1% | 230,297 | -16.3% | 0.65% | -47.2% |
| KYMR | Sell | KYMERA THERAPEUTICS INC | $6,877,000 | -29.3% | 110,920 | -63.1% | 0.59% | -52.6% |
| PMVP | Sell | PMV PHARMACEUTICALS INC | $6,151,000 | +15.5% | 100,000 | -33.3% | 0.53% | -22.6% |
| HRMY | Sell | HARMONY BIOSCIENCES HLDGS IN | $3,615,000 | -61.2% | 100,000 | -63.6% | 0.31% | -74.0% |
| BMYRT | Sell | BRISTOL-MYERS SQUIBB COright 99/99/9999 | $3,485,000 | -71.8% | 5,050,000 | -8.2% | 0.30% | -81.1% |
| ITOS | Sell | ITEOS THERAPEUTICS INC | $3,382,000 | -54.3% | 100,000 | -66.7% | 0.29% | -69.4% |
| OM | Sell | OUTSET MED INC | $2,842,000 | -43.2% | 50,000 | -50.0% | 0.24% | -61.9% |
| PLRX | Sell | PLIANT THERAPEUTICS INC | $1,736,000 | -43.9% | 76,426 | -44.1% | 0.15% | -62.4% |
| RAPT | Exit | RAPT THERAPEUTICS INC | $0 | – | -31,100 | -100.0% | -0.13% | – |
| ARYBU | Exit | ARYA SCIENCES ACQUISTION COunit 06/09/2027 | $0 | – | -100,000 | -100.0% | -0.14% | – |
| CHAQU | Exit | CHARDAN HEALTHCR ACQSTN 2 COunit 99/99/9999 | $0 | – | -200,000 | -100.0% | -0.27% | – |
| AFIB | Exit | ACUTUS MED INC | $0 | – | -75,000 | -100.0% | -0.29% | – |
| NARI | Exit | INARI MED INC | $0 | – | -50,000 | -100.0% | -0.44% | – |
| RLAY | Exit | RELAY THERAPEUTICS INC | $0 | – | -100,000 | -100.0% | -0.54% | – |
| PAND | Exit | PANDION THERAPEUTICS INC | $0 | – | -450,000 | -100.0% | -0.66% | – |
| LSACU | Exit | LIFESCI ACQUISITION CORPunit 03/31/2025 | $0 | – | -400,000 | -100.0% | -0.70% | – |
| INBX | Exit | INHIBRX INC | $0 | – | -311,578 | -100.0% | -0.72% | – |
| UMRX | Exit | UNUM THERAPEUTICS INC | $0 | – | -2,700,000 | -100.0% | -0.81% | – |
| AKUS | Exit | AKOUOS INC | $0 | – | -310,000 | -100.0% | -0.91% | – |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -1.96% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -750,000 | -100.0% | -2.08% | – |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEW | $0 | – | -1,200,000 | -100.0% | -2.28% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -275,000 | -100.0% | -4.94% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -850,000 | -100.0% | -6.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 14 | Q3 2023 | 12.6% |
| KARUNA THERAPEUTICS INC | 14 | Q3 2023 | 5.6% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 23.3% |
| DYNE THERAPEUTICS INC | 13 | Q3 2023 | 4.9% |
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 12.4% |
| OLEMA PHARMACEUTICALS INC | 12 | Q3 2023 | 15.4% |
| DESIGN THERAPEUTICS INC | 11 | Q3 2023 | 8.0% |
| NUVATION BIO INC | 11 | Q3 2023 | 0.0% |
| BICYCLE THERAPEUTICS PLC | 10 | Q2 2023 | 5.7% |
| IDEAYA BIOSCIENCES INC | 9 | Q3 2023 | 9.5% |
View Logos Global Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 18, 2023 | 6,350,000 | 8.1% |
| BICYCLE THERAPEUTICS plc | February 14, 2023 | 1,435,000 | 4.8% |
| Dyne Therapeutics, Inc. | February 14, 2023 | 2,150,000 | 4.1% |
| Design Therapeutics, Inc. | March 31, 2022 | 2,797,501 | 5.0% |
| IDEAYA Biosciences, Inc. | March 18, 2022 | 2,650,000 | 6.9% |
| Aligos Therapeutics, Inc. | February 14, 2022 | ? | ? |
| Cogent Biosciences, Inc. | February 14, 2022 | 150,000 | 0.4% |
| Kezar Life Sciences, Inc. | February 14, 2022 | 1,450,000 | 3.0% |
| Nkarta, Inc. | February 14, 2022 | ? | ? |
| Viridian Therapeutics, Inc.\DE | February 14, 2022 | ? | ? |
View Logos Global Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-01 |
| SC 13G | 2024-02-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-02 |
View Logos Global Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.